← Leaderboards
Karl K Johe
Neuralstem, Inc.
$991,049
Attributed
$991,049
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $491K · FY2005–17$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$991,049 · 2
By mechanism
R43$500,000 · 1
R44$491,049 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Adult”
- Lawrence Corey · Fred Hutchinson Cancer Center$594,628,824
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$397,114,680
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$388,038,550
- Judith S. Currier · University Of California Los Angeles$251,592,913
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$196,603,707
- Carol Nesel · Westat$188,148,170
Research focus
AdultAffectAlzheimer&AposAngiotensin-Converting Enzyme InhibitorsAnimal ModelAttentionBcl2 Gene /ProteinBehaviorBrain Derived Neurotrophic FactorCamp Response Element Binding ProteinClinical EfficacyClinically RelevantClinical ResearchClinical Trials DesignCognitive DeficitsCorneaDefectDensityDiabetes MellitusDiabeticDiabetic NeuropathiesDiabetic PatientDoseAdjuvant
Grant awards (4)
Development of NSI-189, a novel neurogenic molecule, to prevent and treat diabetic neuropathy$491,049
R44 · FY2017 · NS · contact PI
Novel Neurogenic Agents as Depression Therapeutics$250,000
R43 · FY2006 · MH · contact PI
Novel Neurogenic Agents as Depression Therapeutics$41,845
R43 · FY2006 · MH · contact PI
Novel Neurogenic Agents as Depression Therapeutics$208,155
R43 · FY2005 · MH